2-烯丙基-1-(6-(2-羟基丙-2-基)吡啶-2-基)-6-(4-(4-甲基哌嗪-1-基)苯基氨基)-1H-吡唑并[3,4-D]嘧啶-3(2H)-酮

主页 / 产品目录 / API / 2-烯丙基-1-(6-(2-羟基丙-2-基)吡啶-2-基)-6-(4-(4-甲基哌嗪-1-基)苯基氨基)-1H-吡唑并[3,4-D]嘧啶-3(2H)-酮

2-烯丙基-1-(6-(2-羟基丙-2-基)吡啶-2-基)-6-(4-(4-甲基哌嗪-1-基)苯基氨基)-1H-吡唑并[3,4-D]嘧啶-3(2H)-酮

编号ABP000952 化学名称MK-1775/MK1775 CAS955365-80-7 分子式C27H32N8O2 分子量500.5954 纯度 >99%

产品详情
相关中间体
相关产品

化学名称 : 2-烯丙基-1-(6-(2-羟基丙-2-基)吡啶-2-基)-6-(4-(4-甲基哌嗪-1-基)苯基氨基)-1H-吡唑并[3,4-D]嘧啶-3(2H)-酮

CAS : 955365-80-7

英文名称: MK-1775/MK1775

英文同义词: 1,2-Dihydro-1-[6-(1-hydroxy-1-methylethyl)-2-pyridinyl]-6-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-2-(2-propen-1-yl)-3h-pyrazolo[3,4-d]pyrimidin-3-one

溶解度:DMSO

储存条件:at -20℃ 2 years

生物活性

NVP-BEP800 is a novel, fully synthetic, orally bioavailable inhibitor with an IC50 of 0.058 ± 0.006 μM. It binds to the NH2-terminal ATP-binding pocket of Hsp90. Given the mechanism of action, preclinical activity profile, tolerability, and pharmaceutical properties, NVP-BEP800 is an exciting new oral Hsp90 inhibitor warranting further development. ^[1][2]

参考文献

[1] Massey AJ et al. Mol Cancer Ther. 2010 Apr; 9(4):906-19